# Quantum-Si Inc: financial statements, quarterly

QSI · Nasdaq · CIK 1816431 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qsi.md) · [Financials](/companies/qsi/financials.md) · [Filings](/companies/qsi/filings.md) · [Insiders](/companies/qsi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qsi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001816431-24-000020.md) | [0.4 d](/filings/0001816431-26-000011.md) | [0.5](/filings/0001816431-25-000040.md) | [0.6](/filings/0001816431-25-000050.md) | [0.8](/filings/0001816431-25-000066.md) | [1.2 d](/filings/0001816431-26-000011.md) | [0.8](/filings/0001816431-26-000034.md) | [0.6](/filings/0001816431-26-000056.md) | [0.6](/filings/0001816431-25-000066.md) | [0.5 d](/filings/0001816431-26-000011.md) | [0.3](/filings/0001816431-26-000034.md) | [0.3](/filings/0001816431-26-000056.md) |
| Cost of revenue | $m | [0.1](/filings/0001816431-24-000020.md) | [0.2 d](/filings/0001816431-26-000011.md) | [0.2](/filings/0001816431-25-000040.md) | [0.3](/filings/0001816431-25-000050.md) | [0.4](/filings/0001816431-25-000066.md) | [0.6 d](/filings/0001816431-26-000011.md) | [0.4](/filings/0001816431-26-000034.md) | [0.2](/filings/0001816431-26-000056.md) | [0.4](/filings/0001816431-25-000066.md) | [0.3 d](/filings/0001816431-26-000011.md) | [0.2](/filings/0001816431-26-000034.md) | [0.2](/filings/0001816431-26-000056.md) |
| Gross profit | $m | [0.1](/filings/0001816431-24-000020.md) | [0.2 d](/filings/0001816431-26-000011.md) | [0.3](/filings/0001816431-25-000040.md) | [0.4](/filings/0001816431-25-000050.md) | [0.4](/filings/0001816431-25-000066.md) | [0.6 d](/filings/0001816431-26-000011.md) | [0.5](/filings/0001816431-26-000034.md) | [0.4](/filings/0001816431-26-000056.md) | [0.2](/filings/0001816431-25-000066.md) | [0.1 d](/filings/0001816431-26-000011.md) | [0.1](/filings/0001816431-26-000034.md) | [0.2](/filings/0001816431-26-000056.md) |
| Research and development | $m | [16.6](/filings/0001816431-24-000020.md) | [16.4 d](/filings/0001816431-26-000011.md) | [12.1](/filings/0001816431-25-000040.md) | [14.4](/filings/0001816431-25-000050.md) | [16.2](/filings/0001816431-25-000066.md) | [17.0 d](/filings/0001816431-26-000011.md) | [13.7](/filings/0001816431-26-000034.md) | [15.2](/filings/0001816431-26-000056.md) | [13.9](/filings/0001816431-25-000066.md) | [10.9 d](/filings/0001816431-26-000011.md) | [14.5](/filings/0001816431-26-000034.md) | [15.8](/filings/0001816431-26-000056.md) |
| Selling, general and administrative | $m | [10.7](/filings/0001816431-24-000020.md) | [11.6 d](/filings/0001816431-26-000011.md) | [11.5](/filings/0001816431-25-000040.md) | [12.4](/filings/0001816431-25-000050.md) | [12.3](/filings/0001816431-25-000066.md) | [14.3 d](/filings/0001816431-26-000011.md) | [11.9](/filings/0001816431-26-000034.md) | [11.9](/filings/0001816431-26-000056.md) | [10.7](/filings/0001816431-25-000066.md) | [10.3 d](/filings/0001816431-26-000011.md) | [9.6](/filings/0001816431-26-000034.md) | [10.0](/filings/0001816431-26-000056.md) |
| Operating income | $m | [(27.2)](/filings/0001816431-24-000020.md) | [(27.9) d](/filings/0001816431-26-000011.md) | [(23.4)](/filings/0001816431-25-000040.md) | [(26.5)](/filings/0001816431-25-000050.md) | [(28.1)](/filings/0001816431-25-000066.md) | [(30.7) d](/filings/0001816431-26-000011.md) | [(25.1)](/filings/0001816431-26-000034.md) | [(30.1)](/filings/0001816431-26-000056.md) | [(39.8)](/filings/0001816431-25-000066.md) | [(21.1) d](/filings/0001816431-26-000011.md) | [(24.1)](/filings/0001816431-26-000034.md) | [(25.6)](/filings/0001816431-26-000056.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001816431-24-000020.md) | [0.0 d](/filings/0001816431-26-000011.md) | [0.0](/filings/0001816431-25-000040.md) | [0.0](/filings/0001816431-25-000050.md) | [0.0](/filings/0001816431-25-000066.md) | [0.0 d](/filings/0001816431-26-000011.md) | [0.0](/filings/0001816431-26-000034.md) | [0.0](/filings/0001816431-26-000056.md) | [0.0](/filings/0001816431-25-000066.md) | [0.0 d](/filings/0001816431-26-000011.md) | [(0.1)](/filings/0001816431-26-000034.md) | [0.0](/filings/0001816431-26-000056.md) |
| Net income | $m | [(24.7)](/filings/0001816431-24-000020.md) | [(22.0) d](/filings/0001816431-26-000011.md) | [(19.5)](/filings/0001816431-25-000066.md) | [(23.1)](/filings/0001816431-25-000066.md) | [(25.3)](/filings/0001816431-25-000066.md) | [(33.1) d](/filings/0001816431-26-000011.md) | [(19.2)](/filings/0001816431-26-000056.md) | [(28.8)](/filings/0001816431-26-000056.md) | [(35.7)](/filings/0001816431-25-000066.md) | [(17.6) d](/filings/0001816431-26-000011.md) | [(21.7)](/filings/0001816431-26-000056.md) | [(23.5)](/filings/0001816431-26-000056.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001816431-24-000020.md) | not reported | [(0.14)](/filings/0001816431-25-000040.md) | [(0.16)](/filings/0001816431-25-000050.md) | [(0.18)](/filings/0001816431-25-000066.md) | not reported | [(0.11)](/filings/0001816431-26-000034.md) | [(0.16)](/filings/0001816431-26-000056.md) | [(0.17)](/filings/0001816431-25-000066.md) | not reported | [(0.10)](/filings/0001816431-26-000034.md) | [(0.11)](/filings/0001816431-26-000056.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001816431-24-000020.md) | not reported | [(0.14)](/filings/0001816431-25-000040.md) | [(0.16)](/filings/0001816431-25-000050.md) | [(0.18)](/filings/0001816431-25-000066.md) | not reported | [(0.11)](/filings/0001816431-26-000034.md) | [(0.16)](/filings/0001816431-26-000056.md) | [(0.17)](/filings/0001816431-25-000066.md) | not reported | [(0.10)](/filings/0001816431-26-000034.md) | [(0.11)](/filings/0001816431-26-000056.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [93.8](/filings/0001140361-23-052474.md) | [134](/filings/0001816431-25-000014.md) | [53.2](/filings/0001140361-24-025201.md) | [59.6](/filings/0001628280-24-035626.md) | [42.3](/filings/0001816431-24-000020.md) | [49.2](/filings/0001816431-26-000011.md) | [37.3](/filings/0001816431-25-000040.md) | [22.2](/filings/0001816431-26-000056.md) | [30.9](/filings/0001816431-25-000066.md) | [21.6](/filings/0001816431-26-000056.md) | [36.2](/filings/0001816431-26-000034.md) | [23.7](/filings/0001816431-26-000056.md) |
| Current assets | $m | [285](/filings/0001140361-23-052474.md) | [266](/filings/0001816431-25-000014.md) | [244](/filings/0001140361-24-025201.md) | [226](/filings/0001628280-24-035626.md) | [206](/filings/0001816431-24-000020.md) | [218](/filings/0001816431-26-000011.md) | [242](/filings/0001816431-25-000040.md) | [226](/filings/0001816431-25-000050.md) | [238](/filings/0001816431-25-000066.md) | [176](/filings/0001816431-26-000056.md) | [135](/filings/0001816431-26-000034.md) | [119](/filings/0001816431-26-000056.md) |
| Total assets | $m | [318](/filings/0001140361-23-052474.md) | [298](/filings/0001816431-25-000014.md) | [276](/filings/0001140361-24-025201.md) | [257](/filings/0001628280-24-035626.md) | [236](/filings/0001816431-24-000020.md) | [248](/filings/0001816431-26-000011.md) | [271](/filings/0001816431-25-000040.md) | [254](/filings/0001816431-25-000050.md) | [260](/filings/0001816431-25-000066.md) | [246](/filings/0001816431-26-000056.md) | [213](/filings/0001816431-26-000034.md) | [194](/filings/0001816431-26-000056.md) |
| Current liabilities | $m | [11.0](/filings/0001140361-23-052474.md) | [11.6](/filings/0001816431-25-000014.md) | [8.0](/filings/0001140361-24-025201.md) | [11.0](/filings/0001628280-24-035626.md) | [15.3](/filings/0001816431-24-000020.md) | [18.2](/filings/0001816431-26-000011.md) | [12.6](/filings/0001816431-25-000040.md) | [24.0](/filings/0001816431-25-000050.md) | [22.1](/filings/0001816431-25-000066.md) | [23.0](/filings/0001816431-26-000056.md) | [10.7](/filings/0001816431-26-000034.md) | [11.9](/filings/0001816431-26-000056.md) |
| Total liabilities | $m | [26.0](/filings/0001140361-23-052474.md) | [26.6](/filings/0001816431-25-000014.md) | [21.8](/filings/0001140361-24-025201.md) | [23.5](/filings/0001628280-24-035626.md) | [25.9](/filings/0001816431-24-000020.md) | [32.5](/filings/0001816431-26-000011.md) | [24.3](/filings/0001816431-25-000040.md) | [33.4](/filings/0001816431-25-000050.md) | [25.0](/filings/0001816431-25-000066.md) | [25.4](/filings/0001816431-26-000056.md) | [12.6](/filings/0001816431-26-000034.md) | [13.4](/filings/0001816431-26-000056.md) |
| Shareholders' equity | $m | [292](/filings/0001816431-24-000020.md) | [272](/filings/0001816431-26-000011.md) | [254](/filings/0001816431-25-000066.md) | [233](/filings/0001816431-25-000066.md) | [211](/filings/0001816431-25-000066.md) | [215](/filings/0001816431-26-000056.md) | [247](/filings/0001816431-26-000056.md) | [221](/filings/0001816431-26-000056.md) | [235](/filings/0001816431-25-000066.md) | [220](/filings/0001816431-26-000056.md) | [201](/filings/0001816431-26-000056.md) | [180](/filings/0001816431-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.4) d](/filings/0001816431-24-000020.md) | [(21.0) d](/filings/0001816431-26-000011.md) | [(23.2)](/filings/0001816431-25-000040.md) | [(18.6) d](/filings/0001816431-25-000050.md) | [(23.2) d](/filings/0001816431-25-000066.md) | [(22.9) d](/filings/0001816431-26-000011.md) | [(26.2)](/filings/0001816431-26-000034.md) | [(20.2) d](/filings/0001816431-26-000056.md) | [(32.0) d](/filings/0001816431-25-000066.md) | [(16.3) d](/filings/0001816431-26-000011.md) | [(25.6)](/filings/0001816431-26-000034.md) | [(18.4) d](/filings/0001816431-26-000056.md) |
| Capital expenditure | $m | [1.3 d](/filings/0001816431-24-000020.md) | [(0.4) d](/filings/0001816431-26-000011.md) | [1.0](/filings/0001816431-25-000040.md) | [1.1 d](/filings/0001816431-25-000050.md) | [1.0 d](/filings/0001816431-25-000066.md) | [1.4 d](/filings/0001816431-26-000011.md) | [1.3](/filings/0001816431-26-000034.md) | [0.3 d](/filings/0001816431-26-000056.md) | [0.9 d](/filings/0001816431-25-000066.md) | [(0.0) d](/filings/0001816431-26-000011.md) | [0.3](/filings/0001816431-26-000034.md) | [0.1 d](/filings/0001816431-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [140](/filings/0001140361-23-052474.md) | [140](/filings/0001140361-24-025201.md) | [142](/filings/0001628280-24-035626.md) | [142](/filings/0001816431-24-000020.md) | [142](/filings/0001816431-25-000040.md) | [142](/filings/0001816431-25-000050.md) | [142](/filings/0001816431-25-000066.md) | [182](/filings/0001816431-26-000034.md) | [184](/filings/0001816431-26-000056.md) | [209](/filings/0001816431-25-000066.md) | [216](/filings/0001816431-26-000034.md) | [218](/filings/0001816431-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.